Casi pharmaceuticals announces stock repurchase program

Rockville, md. and beijing , dec. 17, 2021 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), (the "company" or "casi"), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that its board of directors approved a stock repurchase program for the repurchase of up to usd 10 million of the company's common stock (and no more than 12,500,000 shares of the company's common stock) through open market purchases in compliance with rule 10b-18 under the securities exchange act of 1934 and through trading plans established pursuant to rule 10b5-1 of the securities exchange act.
CASI Ratings Summary
CASI Quant Ranking